Organigram Global Inc.

NASDAQ:OGI

Drug Manufacturers - Specialty & Generic

Healthcare
$0.68 -1.74%

-$0.02 today

Market cap
$95.40M
Beta
1.84
P/E (TTM)
-7.2
EPS (TTM)
-$0.19
52W Low $0.97High $2.24

Volume 0.62M

Average 0.67M

OGI Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Organigram Global Inc.NASDAQ: OGI

Stock-Based Compensation · Q2 FY2026 · quarter ended Mar 2026

Stock-based compensation declines year over year

Q2 FY2026 stock-based compensation of CA$728K fell 22.4% year over year, ahead of the -36.6% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 5.5% from the prior quarter.

Context

  • Stock-based compensation amounted to 2.3% of revenue in FY2025, down 2.2 pp from a year earlier.
  • Stock-based compensation increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -22.4% holds above the trailing-twelve-month pace of -36.6%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
CA$728K-5.5% QoQ
Last fiscal yearSep 2025
CA$4.22M-41.3% YoY
LTMMar 2026
CA$3.45M-36.6% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-22.4%——
1 year-41.3%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

CAD · from the cash flow

Latest · FY2025
4.22M CAD
Year-over-year change
-41.3%
4-year CAGR
+2.0%

Stock-Based Compensation vs competitors

How OGI compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -36.6% is the 8th highest of 9, against a peer median of +3.7%.
  • Stock-based compensation amounts to 1.3% of revenue for OGI, versus a peer median of 9.2%.
OGI Competitors
Stock-Based Compensation for OGI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IVAInventiva S.A.FY2025€26.77M EUR+647.7%+129.4%597.1%
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026$11.86M USD+7.9%+52.0%36.3%
RNACCartesian Therapeutics, Inc.LTM Mar 2026$10.44M USD+36.3%-2.0%587.9%
HSDTSolana CompanyLTM Mar 2026$8.72M USD+217.8%—90.9%
ACBAurora Cannabis Inc.LTM Mar 2026CA$7.29M CAD-36.7%-24.4%2.3%
DERMJourney Medical CorporationLTM Mar 2026$5.95M USD-1.0%+12.4%9.2%
LFCRLifecore Biomedical, Inc.LTM Mar 2026$5.91M USD—+57.3%4.4%
INFUInfuSystem Holdings, Inc.LTM Mar 2026$4.49M USD-0.5%+4.5%3.2%
OGIOrganigram Global Inc.LTM Mar 2026CA$3.45M CAD-36.6%—1.3%
ELMDElectromed, Inc.LTM Mar 2026$2.61M USD-8.5%+46.3%3.6%
Peer median (excluding OGI) —+3.7%+29.4%9.2%

Competitors are the stored peer set for OGI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

CAD
Metric
FY2021
Aug 2021
FY2022
Aug 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
Net Income(130.7M)(14.28M)(229.48M)(45.44M)(24.76M)
Depreciation & Amortization31.03M24.91M24.08M12.08M17.98M
Deferred Income Tax42.21M(88K)(2.66M)0(13.77M)
Stock-Based Compensation3.9M5.13M5.29M7.18M4.22M
Change in Working Capital24.2M(22.88M)12.51M14.96M(2.12M)
Accounts Receivables(6.01M)(24.02M)12.51M(12.06M)(15.29M)
Inventory28.68M(12.22M)000
Accounts Payables2.06M12.15M000
Other Working Capital(542K)1.21M(4.06M)27.02M13.16M
Other Non-Cash Items776K(29M)151.8M15.09M14.16M
Operating Cash Flow(28.59M)(36.21M)(35.8M)3.87M(4.3M)
Capital Expenditures(12.33M)(48.78M)(26.9M)(5.34M)(12.22M)
Acquisitions (Net)(2.54M)(11.06M)00(65.62M)
Purchases of Investments(120.02M)(15M)(7.36M)(29.24M)(1.01M)
Sales of Investments50.85M114.59M36.37M3.52M2.5M
Other Investing Activities(31.08M)4.29M31.46M(8.32M)21.8M
Investing Cash Flow(115.11M)44.03M4.56M(38.77M)(59.35M)
Debt Repayment(116.4M)(1.01M)(64.04K)(786K)(43.08K)
Common Stock Issued284.88M6.34M20K108.56M29.57M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities5.99M6.34M(754.15K)6K(1.29M)
Financing Cash Flow174.46M5.33M(754.15K)107.78M28.24M
Effect of Forex Changes0000(2.57M)
Net Change in Cash30.77M13.15M(68.52M)72.88M(37.98M)
Free Cash Flow(40.92M)(84.99M)(62.7M)(1.47M)(16.52M)

Organigram Global Inc.

NASDAQ:OGI

Intrinsic Alpha fair value

Locked

Current Price

$0.68

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.